Optibrium, a developer of software for drug discovery, has released version 5.4 of its StarDropÂ™ software platform.
The company says the new release offers enhanced features to guide the design of novel, safe and efficacious drugs by providing access to world-leading technologies for toxicity prediction and bioisosteric transformations. These new optional modules further extend StarDropÂ’s capabilities to intuitively target high-quality compounds in drug discovery, reducing the time and cost to deliver drug candidates with an improved chance of success.
The new Derek NexusÂ™ module for StarDrop, developed in collaboration with Lhasa Limited, provides knowledge-based predictions of the likelihood of a compound causing toxicity in more than 40 endpoints, including mutagenicity, carcinogenicity and hepatotoxicity.
Integrated with StarDropÂ’s Glowing MoleculeÂ™ visualisation, this new module guides the redesign of compounds to reduce the potential for toxicity, the company says. An easy-to-use reporting feature facilitates collaboration between chemists and expert toxicologists to interpret the results, enabling effective, timely decision-making regarding the prioritisation of chemistries early in the drug discovery process.